Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References H2 2021 sales and core Oplnc growth expected to accelerate as healthcare systems return to normal Group growth vs. PY illustrative %pts, cc Sales 3% Mid single digit Low to mid single digit ☐ H2 2021 sales¹ Growth acceleration as we expect continuation of the return to normal global healthcare systems including prescription dynamics, particularly in oncology H1 2021 H2 2021 FY 2021 ■ Sandoz stabilization Core Oplnc 2% H1 2021 High single digit Mid single digit H2 2021 FY 2021 1. Assumes no GilenyaⓇ and no Sandostatin® LAR generics enter in the US. 36 Investor Relations | Q2 2021 Results H2 2021 Core operating income ■ Driven by higher sales Increased investments in growth drivers as markets reopen, and pipeline (incl. tislelizumab) Ongoing productivity programs NOVARTIS | Reimagining Medicine

View entire presentation